KeystoneHeart Release:New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR

Published: May 23, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PARIS and CAESAREA, Israel, May 22, 2013 /PRNewswire/ --

•New clinical data presented from the DEFLECT-I study demonstrates that Keystone Heart's TriGuard™ Cerebral Protection Device reduces brain lesion volume during TAVR (Transcatheter Aortic Valve Replacement) procedures when compared to historical data.

Help employers find you! Check out all the jobs and post your resume.

Back to news